Prasad S Adusumilli
Cited by
Cited by
Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition
L Cherkassky, A Morello, J Villena-Vargas, Y Feng, DS Dimitrov, ...
The Journal of clinical investigation 126 (8), 3130-3144, 2016
Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity
PS Adusumilli, L Cherkassky, J Villena-Vargas, C Colovos, E Servais, ...
Science translational medicine 6 (261), 261ra151-261ra151, 2014
Tumor spread through air spaces is an important pattern of invasion and impacts the frequency and location of recurrences after limited resection for small stage I lung …
K Kadota, J Nitadori, CS Sima, H Ujiie, NP Rizk, DR Jones, PS Adusumilli, ...
Journal of Thoracic Oncology 10 (5), 806-814, 2015
Mesothelin-targeted CARs: driving T cells to solid tumors
A Morello, M Sadelain, PS Adusumilli
Cancer discovery 6 (2), 133-146, 2016
Mesothelioma: Scientific clues for prevention, diagnosis, and therapy
M Carbone, PS Adusumilli, HR Alexander Jr, P Baas, F Bardelli, A Bononi, ...
CA: a cancer journal for clinicians 69 (5), 402-429, 2019
Combination immunotherapy with CAR T cells and checkpoint blockade for the treatment of solid tumors
R Grosser, L Cherkassky, N Chintala, PS Adusumilli
Cancer cell 36 (5), 471-482, 2019
Loss of BAP1 function leads to EZH2-dependent transformation
LM LaFave, W Béguelin, R Koche, M Teater, B Spitzer, A Chramiec, ...
Nature medicine 21 (11), 1344-1349, 2015
Scientific advances in lung cancer 2015
AS Tsao, GV Scagliotti, PA Bunn Jr, DP Carbone, GW Warren, C Bai, ...
Journal of Thoracic Oncology 11 (5), 613-638, 2016
Long-term survival based on the surgical approach to lobectomy for clinical stage I nonsmall cell lung cancer: comparison of robotic, video-assisted thoracic surgery, and …
HX Yang, KM Woo, CS Sima, MS Bains, PS Adusumilli, J Huang, ...
Annals of surgery 265 (2), 431-437, 2017
Cisplatin-induced antitumor immunomodulation: a review of preclinical and clinical evidence
AR de Biasi, J Villena-Vargas, PS Adusumilli
Clinical Cancer Research 20 (21), 5384-5391, 2014
A phase I trial of regional mesothelin-targeted CAR T-cell therapy in patients with malignant pleural disease, in combination with the anti–PD-1 agent pembrolizumab
PS Adusumilli, MG Zauderer, I Rivière, SB Solomon, VW Rusch, ...
Cancer discovery 11 (11), 2748-2763, 2021
Impact of micropapillary histologic subtype in selecting limited resection vs lobectomy for lung adenocarcinoma of 2cm or smaller
J Nitadori, AJ Bograd, K Kadota, CS Sima, NP Rizk, EA Morales, ...
Journal of the National Cancer Institute 105 (16), 1212-1220, 2013
IASLC multidisciplinary recommendations for pathologic assessment of lung cancer resection specimens after neoadjuvant therapy
WD Travis, S Dacic, I Wistuba, L Sholl, P Adusumilli, L Bubendorf, P Bunn, ...
Journal of Thoracic Oncology 15 (5), 709-740, 2020
Pretreatment neutrophil-to-lymphocyte ratio and mutational burden as biomarkers of tumor response to immune checkpoint inhibitors
C Valero, M Lee, D Hoen, K Weiss, DW Kelly, PS Adusumilli, PK Paik, ...
Nature communications 12 (1), 729, 2021
Initial results of pulmonary resection after neoadjuvant nivolumab in patients with resectable non–small cell lung cancer
MJ Bott, SC Yang, BJ Park, PS Adusumilli, VW Rusch, JM Isbell, ...
The Journal of thoracic and cardiovascular surgery 158 (1), 269-276, 2019
Prognostic significance of adenocarcinoma in situ, minimally invasive adenocarcinoma, and nonmucinous lepidic predominant invasive adenocarcinoma of the lung in patients with …
K Kadota, J Villena-Vargas, A Yoshizawa, N Motoi, CS Sima, GJ Riely, ...
The American journal of surgical pathology 38 (4), 448-460, 2014
Mesothelin overexpression promotes mesothelioma cell invasion and MMP-9 secretion in an orthotopic mouse model and in epithelioid pleural mesothelioma patients
EL Servais, C Colovos, L Rodriguez, AJ Bograd, J Nitadori, C Sima, ...
Clinical Cancer Research 18 (9), 2478-2489, 2012
Solid predominant histologic subtype in resected stage I lung adenocarcinoma is an independent predictor of early, extrathoracic, multisite recurrence and of poor …
H Ujiie, K Kadota, JE Chaft, D Buitrago, CS Sima, MC Lee, J Huang, ...
Journal of clinical oncology 33 (26), 2877-2884, 2015
Clinical impact of immune microenvironment in stage I lung adenocarcinoma: tumor interleukin-12 receptor β2 (IL-12Rβ2), IL-7R, and stromal FoxP3/CD3 ratio are independent …
K Suzuki, K Kadota, CS Sima, J Nitadori, VW Rusch, WD Travis, ...
Journal of clinical oncology 31 (4), 490-498, 2013
Prognostic immune markers in non–small cell lung cancer
K Suzuki, SS Kachala, K Kadota, R Shen, Q Mo, DG Beer, VW Rusch, ...
Clinical Cancer Research 17 (16), 5247-5256, 2011
The system can't perform the operation now. Try again later.
Articles 1–20